Translating phage therapy into the clinic: Recent accomplishments but continuing challenges.

Aleksandra Petrovic Fabijan, Jonathan Iredell, Katarzyna Danis-Wlodarczyk, Razieh Kebriaei, Stephen T Abedon
Author Information
  1. Aleksandra Petrovic Fabijan: Centre for Infectious Diseases and Microbiology, Westmead Institute for Medical Research, Westmead, New South Wales, Australia.
  2. Jonathan Iredell: Centre for Infectious Diseases and Microbiology, Westmead Institute for Medical Research, Westmead, New South Wales, Australia.
  3. Katarzyna Danis-Wlodarczyk: Department of Microbial Infection and Immunity, The Ohio State University, Columbus, Ohio, United States of America.
  4. Razieh Kebriaei: P3 Research Laboratory, College of Pharmacy, The Ohio State University, Columbus, Ohio, United States of America.
  5. Stephen T Abedon: Department of Microbiology, The Ohio State University, Mansfield, Ohio, United States of America.

Abstract

Phage therapy is a medical form of biological control of bacterial infections, one that uses naturally occurring viruses, called bacteriophages or phages, as antibacterial agents. Pioneered over 100 years ago, phage therapy nonetheless is currently experiencing a resurgence in interest, with growing numbers of clinical case studies being published. This renewed enthusiasm is due in large part to phage therapy holding promise for providing safe and effective cures for bacterial infections that traditional antibiotics acting alone have been unable to clear. This Essay introduces basic phage biology, provides an outline of the long history of phage therapy, highlights some advantages of using phages as antibacterial agents, and provides an overview of recent phage therapy clinical successes. Although phage therapy has clear clinical potential, it faces biological, regulatory, and economic challenges to its further implementation and more mainstream acceptance.

References

  1. Microbiol Spectr. 2017 Aug;5(4): [PMID: 28840811]
  2. Pharmacotherapy. 2020 Feb;40(2):153-168 [PMID: 31872889]
  3. Zh Mikrobiol Epidemiol Immunobiol. 1992 Mar;(3):30-3 [PMID: 1380753]
  4. Ann Intern Med. 2019 Dec 17;171(12):940-941 [PMID: 31525739]
  5. Nat Commun. 2022 May 3;13(1):2313 [PMID: 35504908]
  6. Lancet Infect Dis. 2020 May;20(5):e90-e101 [PMID: 32213334]
  7. PLoS Biol. 2006 Jan;4(1):e3 [PMID: 16336043]
  8. Emerg Microbes Infect. 2021 Dec;10(1):2205-2219 [PMID: 34736365]
  9. J Biomed Sci. 2022 Mar 30;29(1):23 [PMID: 35354477]
  10. EMBO Mol Med. 2021 Sep 7;13(9):e13936 [PMID: 34369652]
  11. Curr Opin Virol. 2022 Feb;52:24-29 [PMID: 34801778]
  12. Commun Biol. 2019 Nov 4;2:405 [PMID: 31701033]
  13. Drug Discov Today. 2021 Sep;26(9):2095-2098 [PMID: 34237459]
  14. Ups J Med Sci. 2019 Nov;124(4):218-227 [PMID: 31724901]
  15. Pharmaceuticals (Basel). 2021 Oct 03;14(10): [PMID: 34681243]
  16. J Antibiot (Tokyo). 2018 Feb;71(2):153-184 [PMID: 28676714]
  17. Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3188-92 [PMID: 8622911]
  18. J Immunol. 2018 May 1;200(9):3037-3044 [PMID: 29685950]
  19. Trends Ecol Evol. 2013 Feb;28(2):110-8 [PMID: 23040463]
  20. Phage (New Rochelle). 2022 Jun 1;3(2):112-115 [PMID: 36157289]
  21. J Bacteriol. 2007 Jun;189(11):4223-33 [PMID: 17337582]
  22. Environ Microbiol. 2019 Jun;21(6):2095-2111 [PMID: 30888719]
  23. Bacteriophage. 2011 Mar;1(2):111-114 [PMID: 22334867]
  24. Arch Immunol Ther Exp (Warsz). 1987;35(5):569-83 [PMID: 3455647]
  25. Nat Biotechnol. 2019 Jun;37(6):581-586 [PMID: 31068679]
  26. Clin Microbiol Rev. 2019 Jan 16;32(2): [PMID: 30651225]
  27. mBio. 2019 Jun 4;10(3): [PMID: 31164468]
  28. Res Microbiol. 2018 Nov;169(9):540-542 [PMID: 29777836]
  29. Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4107-12 [PMID: 11259652]
  30. J Immunol. 1956 Mar;76(3):209-16 [PMID: 13306956]
  31. Antibiotics (Basel). 2022 Sep 30;11(10): [PMID: 36289998]
  32. mBio. 2020 Aug 4;11(4): [PMID: 32753497]
  33. Viruses. 2019 Mar 17;11(3): [PMID: 30884879]
  34. Antimicrob Agents Chemother. 2020 Jun 23;64(7): [PMID: 32393490]
  35. Viruses. 2019 Mar 19;11(3): [PMID: 30893844]
  36. Evol Med Public Health. 2018 Mar 08;2018(1):60-66 [PMID: 29588855]
  37. Clin Microbiol Rev. 2022 Dec 21;35(4):e0006222 [PMID: 36069758]
  38. Antibiotics (Basel). 2018 Feb 13;7(1): [PMID: 29438355]
  39. BioDrugs. 2021 May;35(3):255-280 [PMID: 33881767]
  40. J Bacteriol. 2008 Apr;190(8):3083-7 [PMID: 18263725]
  41. Front Microbiol. 2017 Jul 26;8:1386 [PMID: 28798729]
  42. Nat Microbiol. 2021 Feb;6(2):157-161 [PMID: 33432151]
  43. Trends Microbiol. 2013 May;21(5):215-20 [PMID: 23540830]
  44. Antimicrob Agents Chemother. 2019 Dec 20;64(1): [PMID: 31611357]
  45. Curr Opin Biotechnol. 2021 Apr;68:251-261 [PMID: 33714050]
  46. Clin Pharmacokinet. 2003;42(4):315-25 [PMID: 12648024]
  47. Lancet. 2022 Feb 12;399(10325):629-655 [PMID: 35065702]
  48. Proc Natl Acad Sci U S A. 2018 Jan 9;115(2):337-342 [PMID: 29259110]
  49. Bacteriophage. 2011 Jan;1(1):52-53 [PMID: 21687536]
  50. RNA Biol. 2014;11(1):42-4 [PMID: 24457913]
  51. Virology. 2013 Sep 1;443(2):187-96 [PMID: 23755967]
  52. Folia Microbiol (Praha). 2010 May;55(3):221-7 [PMID: 20526833]
  53. Bacteriophage. 2012 Apr 1;2(2):130-133 [PMID: 23050223]
  54. Viruses. 2021 Jun 29;13(7): [PMID: 34209836]
  55. Proc Natl Acad Sci U S A. 2020 May 26;117(21):11207-11216 [PMID: 32424102]
  56. Virus Res. 2018 Jan 15;244:181-193 [PMID: 29175107]
  57. Proc Natl Acad Sci U S A. 2013 Jun 25;110(26):10771-6 [PMID: 23690590]
  58. Cell Host Microbe. 2019 Jun 12;25(6):803-814.e5 [PMID: 31175044]
  59. PLoS One. 2008;3(12):e3957 [PMID: 19088849]
  60. Clin Infect Dis. 2017 Jun 01;64(11):1582-1588 [PMID: 28329379]
  61. Lancet. 2005 Jun 25-Jul 1;365(9478):2166-7 [PMID: 15986542]
  62. Clin Ther. 2020 Sep;42(9):1659-1680 [PMID: 32883528]
  63. Public Health Ethics. 2020 Feb 20;13(1):82-88 [PMID: 32760449]
  64. Med J Aust. 2019 Aug;211(3):142-143.e1 [PMID: 31281964]
  65. Adv Virus Res. 2021;111:63-110 [PMID: 34663499]
  66. Archaea. 2013;2013:251245 [PMID: 23653528]
  67. Am J Respir Crit Care Med. 2019 Nov 1;200(9):1179-1181 [PMID: 31437402]
  68. J Virol. 2014 Nov;88(21):12551-7 [PMID: 25142581]
  69. Adv Appl Microbiol. 2010;70:217-48 [PMID: 20359459]
  70. Cell Host Microbe. 2019 Feb 13;25(2):219-232 [PMID: 30763536]
  71. Methods Mol Biol. 2018;1693:159-170 [PMID: 29119440]
  72. Duke Law J. 2019 Jan;68(4):767-805 [PMID: 30649837]
  73. Front Microbiol. 2016 Sep 08;7:1391 [PMID: 27660625]
  74. Adv Exp Med Biol. 2019;1148:233-253 [PMID: 31482502]
  75. Scientifica (Cairo). 2012;2012:734023 [PMID: 24278736]
  76. Antibiotics (Basel). 2019 Oct 11;8(4): [PMID: 31614449]
  77. Viruses. 2021 Mar 18;13(3): [PMID: 33803862]
  78. Clin Infect Dis. 2023 Jan 6;76(1):103-112 [PMID: 35676823]
  79. mBio. 2022 Jun 28;13(3):e0078322 [PMID: 35506667]
  80. Viruses. 2019 Apr 17;11(4): [PMID: 30999559]
  81. Front Microbiol. 2020 Jun 03;11:1171 [PMID: 32582107]
  82. Sci Rep. 2015 Oct 06;5:14802 [PMID: 26440922]
  83. Curr Opin Microbiol. 2011 Oct;14(5):519-23 [PMID: 21900036]
  84. Trends Microbiol. 2016 Apr;24(4):249-256 [PMID: 26786863]
  85. Nat Commun. 2021 Oct 6;12(1):5845 [PMID: 34615859]
  86. Bacteriol Rev. 1976 Dec;40(4):793-802 [PMID: 795414]
  87. Cell. 2019 Oct 3;179(2):459-469.e9 [PMID: 31585083]
  88. FEMS Microbiol Lett. 2009 Jun;295(2):211-7 [PMID: 19453513]
  89. Lancet Microbe. 2023 Mar;4(3):e126 [PMID: 36868251]
  90. Emerg Microbes Infect. 2021 Dec;10(1):612-618 [PMID: 33703996]
  91. Viral Immunol. 2014 Aug;27(6):295-304 [PMID: 24893003]
  92. Phage (New Rochelle). 2022 Jun 1;3(2):98-111 [PMID: 36148139]
  93. Nat Microbiol. 2020 Mar;5(3):465-472 [PMID: 32066959]
  94. Proc Natl Acad Sci U S A. 1997 Oct 28;94(22):12106-11 [PMID: 9342370]
  95. Cell Mol Life Sci. 2005 Mar;62(5):511-9 [PMID: 15747058]
  96. Bioessays. 2013 Jun;35(6):501 [PMID: 23575903]
  97. Sci Rep. 2016 May 26;6:26717 [PMID: 27225966]
  98. Cell. 2022 Aug 4;185(16):2879-2898.e24 [PMID: 35931020]
  99. Microbiology (Reading). 2013 Jun;159(Pt 6):1023-1035 [PMID: 23579685]
  100. Med Mal Infect. 2008 Aug;38(8):426-30 [PMID: 18687542]
  101. Antibiotics (Basel). 2023 Apr 07;12(4): [PMID: 37107086]
  102. Nat Rev Microbiol. 2017 Jul;15(7):397-408 [PMID: 28461690]
  103. Trends Microbiol. 2022 Jun;30(6):544-552 [PMID: 34872824]
  104. Curr Opin Virol. 2022 Apr;53:101209 [PMID: 35240424]
  105. Viruses. 2018 Apr 05;10(4): [PMID: 29621199]
  106. Adv Appl Microbiol. 2009;67:1-45 [PMID: 19245935]
  107. Viruses. 2021 Feb 21;13(2): [PMID: 33670028]
  108. Pharmaceuticals (Basel). 2021 Jun 30;14(7): [PMID: 34208847]
  109. JAMA Otolaryngol Head Neck Surg. 2019 Aug 01;145(8):723-729 [PMID: 31219531]
  110. Bioessays. 2017 Dec;39(12): [PMID: 28983932]
  111. Clin Microbiol Infect. 2006 Mar;12(3):248-53 [PMID: 16451412]
  112. Crit Rev Microbiol. 2013 Nov;39(4):427-34 [PMID: 22991936]
  113. Front Microbiol. 2016 Oct 24;7:1681 [PMID: 27822205]
  114. Curr Pharm Biotechnol. 2010 Jan;11(1):15-27 [PMID: 20214605]
  115. AIMS Microbiol. 2017 Mar 31;3(2):186-226 [PMID: 31294157]
  116. Adv Virus Res. 2012;83:41-71 [PMID: 22748808]
  117. Pharmaceuticals (Basel). 2021 Nov 15;14(11): [PMID: 34832944]
  118. ISME J. 2017 Jul;11(7):1511-1520 [PMID: 28291233]
  119. Biotechnol Lett. 2007 Jul;29(7):995-1003 [PMID: 17364214]
  120. Clin Pharmacol Ther. 2000 Sep;68(3):225-30 [PMID: 11014403]
  121. Front Cell Infect Microbiol. 2021 Aug 16;11:684704 [PMID: 34485172]
  122. Nat Biotechnol. 2004 Jan;22(1):31-6 [PMID: 14704699]
  123. Lancet Infect Dis. 2021 Mar;21(3):427-436 [PMID: 32949500]
  124. Open Biol. 2021 Sep;11(9):210188 [PMID: 34520699]
  125. FEMS Microbiol Rev. 2020 Nov 24;44(6):684-700 [PMID: 32472938]
  126. Proc Natl Acad Sci U S A. 2020 Aug 4;117(31):18670-18679 [PMID: 32675236]
  127. FEMS Microbiol Lett. 2016 Apr;363(7): [PMID: 26925588]
  128. Annu Rev Microbiol. 2001;55:437-51 [PMID: 11544363]
  129. Bacteriophage. 2011 May;1(3):174-178 [PMID: 22164351]
  130. Front Pharmacol. 2021 Jun 10;12:692614 [PMID: 34177601]
  131. Curr Pharm Biotechnol. 2010 Jan;11(1):69-86 [PMID: 20214609]
  132. J Biotechnol. 2005 Jan 12;115(1):101-7 [PMID: 15607229]
  133. Antibiotics (Basel). 2023 Jan 25;12(2): [PMID: 36830158]
  134. Appl Environ Microbiol. 2021 Jul 13;87(15):e0046821 [PMID: 34020940]
  135. Viruses. 2019 Mar 11;11(3): [PMID: 30862096]
  136. Nat Rev Genet. 2020 Feb;21(2):119-131 [PMID: 31611667]
  137. Viruses. 2021 Aug 05;13(8): [PMID: 34452408]
  138. Mayo Clin Proc. 2011 Feb;86(2):156-67 [PMID: 21282489]
  139. Phage (New Rochelle). 2022 Jun 1;3(2):81-84 [PMID: 36157283]
  140. Methods Mol Biol. 2018;1693:151-158 [PMID: 29119439]
  141. Appl Environ Microbiol. 2014 Sep;80(17):5340-8 [PMID: 24951790]
  142. Curr Opin Virol. 2022 Feb;52:236-243 [PMID: 34971929]
  143. Expert Opin Drug Saf. 2021 Apr;20(4):397-409 [PMID: 33557651]
  144. Adv Virus Res. 2012;83:3-40 [PMID: 22748807]
  145. Phage (New Rochelle). 2020 Mar 1;1(1):16-22 [PMID: 36147613]
  146. Front Microbiol. 2021 Jun 17;12:658374 [PMID: 34220747]
  147. FEMS Immunol Med Microbiol. 2002 Oct 11;34(2):135-8 [PMID: 12381464]
  148. Med Res Rev. 2019 Sep;39(5):2000-2025 [PMID: 30887551]
  149. PLoS Pathog. 2019 Aug 8;15(8):e1007878 [PMID: 31393945]
  150. Antibiotics (Basel). 2020 May 21;9(5): [PMID: 32455557]
  151. J Hist Med Allied Sci. 2018 Oct 1;73(4):385-411 [PMID: 30312428]
  152. Bacteriophage. 2011 Mar;1(2):66-85 [PMID: 22334863]
  153. Clin Otolaryngol. 2009 Aug;34(4):349-57 [PMID: 19673983]
  154. Curr Issues Mol Biol. 2021;40:81-164 [PMID: 32503951]
  155. Clin Microbiol Infect. 2023 May;29(5):565-567 [PMID: 36736660]
  156. Microbiol Mol Biol Rev. 2019 Oct 30;83(4): [PMID: 31666296]
  157. Environ Microbiol. 2016 Jul;18(7):2237-45 [PMID: 26971586]
  158. Cell. 2022 May 26;185(11):1860-1874.e12 [PMID: 35568033]
  159. Antibiotics (Basel). 2022 Aug 30;11(9): [PMID: 36139953]
  160. FEMS Microbiol Lett. 2016 Feb;363(4): [PMID: 26755501]
  161. Bioessays. 2011 Apr;33(4):248-54 [PMID: 21328413]
  162. Future Microbiol. 2015;10(5):685-8 [PMID: 26000644]
  163. Curr Opin Microbiol. 2007 Oct;10(5):461-72 [PMID: 17904412]
  164. Int J Biol Sci. 2021 Aug 18;17(13):3573-3582 [PMID: 34512166]
  165. JAMA. 2023 Mar 14;329(10):781-784 [PMID: 36811929]
  166. Virus Res. 2005 Dec;114(1-2):101-3 [PMID: 16055223]
  167. P T. 2015 Apr;40(4):277-83 [PMID: 25859123]
  168. PLoS One. 2017 Jan 11;12(1):e0168615 [PMID: 28076361]
  169. Cell. 2023 Jan 5;186(1):17-31 [PMID: 36608652]
  170. Proc Natl Acad Sci U S A. 2017 Dec 19;114(51):13531-13536 [PMID: 29208718]
  171. Curr Pharm Biotechnol. 2010 Jan;11(1):28-47 [PMID: 20214606]
  172. Antimicrob Agents Chemother. 2017 Sep 22;61(10): [PMID: 28807909]
  173. Antibiotics (Basel). 2021 Dec 06;10(12): [PMID: 34943709]
  174. Antimicrob Agents Chemother. 2022 Jul 19;66(7):e0224721 [PMID: 35708333]
  175. Adv Drug Deliv Rev. 2019 May;145:18-39 [PMID: 31708017]
  176. Antimicrob Agents Chemother. 2022 Mar 15;66(3):e0207121 [PMID: 35041506]
  177. Bacteriophage. 2016 Aug 11;6(3):e1220348 [PMID: 27738558]
  178. J Hist Med Allied Sci. 1982 Apr;37(2):222-5 [PMID: 6806352]
  179. Curr Opin Virol. 2022 Apr;53:101201 [PMID: 35180532]
  180. Annu Rev Med. 2022 Jan 27;73:197-211 [PMID: 34428079]
  181. Pharmaceuticals (Basel). 2021 Nov 13;14(11): [PMID: 34832939]
  182. Proc Natl Acad Sci U S A. 2007 Jul 3;104(27):11197-202 [PMID: 17592147]
  183. Viruses. 2022 May 28;14(6): [PMID: 35746642]
  184. J Microbiol. 2011 Dec;49(6):994-9 [PMID: 22203564]
  185. Nat Med. 2019 May;25(5):730-733 [PMID: 31068712]
  186. Evol Bioinform Online. 2007 Feb 28;1:97-110 [PMID: 19325857]
  187. Antibiotics (Basel). 2020 May 05;9(5): [PMID: 32380707]
  188. Cell Host Microbe. 2017 Jul 12;22(1):38-47.e4 [PMID: 28704651]
  189. BMC Urol. 2017 Sep 26;17(1):90 [PMID: 28950849]
  190. Lancet Infect Dis. 2022 Aug;22(8):e208-e220 [PMID: 35248167]
  191. Med Microbiol Immunol. 2006 Sep;195(3):143-50 [PMID: 16447074]
  192. Viruses. 2018 Feb 06;10(2): [PMID: 29415431]
  193. BMJ Open. 2022 Dec 9;12(12):e065401 [PMID: 36600337]
  194. Future Microbiol. 2013 Jul;8(7):821-3 [PMID: 23841627]
  195. Clin Infect Dis. 2020 Apr 15;70(9):1998-2001 [PMID: 31414123]
  196. Science. 2021 Oct 22;374(6566):488-492 [PMID: 34672730]
  197. Viruses. 2021 Sep 23;13(10): [PMID: 34696331]
  198. Phage (New Rochelle). 2022 Jun 1;3(2):95-97 [PMID: 36157282]
  199. J Hyg (Lond). 1936 Jun;36(2):204-35 [PMID: 20475326]
  200. Nutrients. 2019 Mar 20;11(3): [PMID: 30897686]
  201. Clin Infect Dis. 2019 Nov 13;69(11):2015-2018 [PMID: 30869755]
  202. Front Microbiol. 2015 Apr 23;6:343 [PMID: 25954266]
  203. Clin Infect Dis. 2021 Jul 1;73(1):e144-e151 [PMID: 32699879]
  204. FEMS Microbiol Rev. 2022 Jan 18;46(1): [PMID: 34289033]
  205. Front Cell Infect Microbiol. 2018 Oct 23;8:376 [PMID: 30406049]
  206. Am J Transplant. 2019 Sep;19(9):2631-2639 [PMID: 31207123]
  207. J Med Microbiol. 2020 Feb;69(2):309-323 [PMID: 32011231]
  208. Viruses. 2019 Apr 12;11(4): [PMID: 31013833]
  209. Bacteriophage. 2013 Apr 1;3(2):e24872 [PMID: 24228220]

Grants

  1. R01 AI169865/NIAID NIH HHS
  2. R21 AI156304/NIAID NIH HHS

MeSH Term

Phage Therapy
Anti-Bacterial Agents
Bacteriophages
Emotions

Chemicals

Anti-Bacterial Agents

Word Cloud

Created with Highcharts 10.0.0therapyphageclinicalbiologicalbacterialinfectionsphagesantibacterialagentsclearprovideschallengesPhagemedicalformcontroloneusesnaturallyoccurringvirusescalledbacteriophagesPioneered100yearsagononethelesscurrentlyexperiencingresurgenceinterestgrowingnumberscasestudiespublishedrenewedenthusiasmduelargepartholdingpromiseprovidingsafeeffectivecurestraditionalantibioticsactingaloneunableEssayintroducesbasicbiologyoutlinelonghistoryhighlightsadvantagesusingoverviewrecentsuccessesAlthoughpotentialfacesregulatoryeconomicimplementationmainstreamacceptanceTranslatingclinic:Recentaccomplishmentscontinuing

Similar Articles

Cited By